Indicator Explainer
Amikacin
A broad-spectrum semi-synthetic aminoglycoside antibiotic, derived from kanamycin with antimicrobial property. Amikacin irreversibly binds to the bacterial 30S ribosomal subunit, specifically locking 16S rRNA and S12 protein within the 30S subunit. This leads to interference with translational initiation complex and misreading of mRNA, thereby hampering protein synthesis and resulting in bactericidal effect. This agent is usually used in short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria.
This page explains what the indicator is and how results are interpreted in general terms. Reference ranges depend on the laboratory, the method, and your own situation — no single “normal value” applies to everyone. This page is health information, not a diagnosis. For symptoms, treatment, or urgent concerns, contact a healthcare professional.
When it is tested
Source: National Cancer Institute, NCI Thesaurus 26.09d, C61615. NCI definition, reproduced without modification under CC BY 4.0. Source identity and definition checked automatically on 2026-10-20. No individual clinical interpretation or human reviewer is asserted.
Reading results
Reference intervals and interpretation depend on the laboratory, specimen, method and clinical context. This source definition is educational information; it does not establish a diagnosis, product approval or suitability for an individual.
Also Known As
References
- NCI Thesaurus 26.09d — Amikacin (C61615)
- Source: National Cancer Institute, NCI Thesaurus 26.09d, C61615. NCI definition, reproduced without modification under CC BY 4.0.
- Optimising empirical therapy for actinomycetoma in diagnostic-limited settings: Prioritising Amikacin and Linezolid via an Integrated Evidence-Concordance Framework. — Trop Doct, 2026-10-15 (PMID 42878530; literature)
- Surface charge-dependent effects of BSA-curcumin nanoparticles combined with amikacin in antimicrobial photodynamic therapy: A pilot In Vivo study of multidrug-resistant Pseudomonas aeruginosa skin infection. — Lasers Med Sci, 2026-10-06 (PMID 42837086; literature)
- Cavitary status and differential treatment response in refractory or severe Mycobacterium avium complex pulmonary disease: Amikacin liposome inhalation suspension versus intravenous amikacin. — Respir Med, 2026-10-23 (PMID 42918261; literature)